Abstract: Object Recent technological developments open the field of therapeutic application of focused ultrasound to the brain through the intact cranium. The goal of this study was to apply the new transcranial magnetic resonance imaging-guided focused ultrasound (tcMRgFUS) technology to perform noninvasive central lateral thalamotomies (CLTs) as a treatment for chronic neuropathic pain. Methods In 12 patients suffering from chronic therapy-resistant neuropathic pain, tcMRgFUS CLT was proposed. In 11 patients, precisely localized thermal ablations of 3-4 mm in diameter were produced in the posterior part of the central lateral thalamic nucleus at peak temperatures between 51°C and 64°C with the aid of real-time patient monitoring and MR imaging and MR thermometry guidance. The treated neuropathic pain syndromes had peripheral (5 patients) or central (6 patients) origins and covered all body parts (face, arm, leg, trunk, and hemibody). Results Patients experienced mean pain relief of 49% at the 3-month follow-up (9 patients) and 57% at the 1-year follow-up (8 patients). Mean improvement according to the visual analog scale amounted to 42% at 3 months and 41% at 1 year. Six patients experienced immediate and persisting somatosensory improvements. Somatosensory and vestibular clinical manifestations were always observed during sonication time because of ultrasound-based neuronal activation and/or initial therapeutic effects. Quantitative electroencephalography (EEG) showed a significant reduction in EEG spectral overactivities. Thermal ablation sites showed sharply delineated ellipsoidal thermolesions surrounded by short-lived vasogenic edema. Lesion reconstructions (18 lesions in 9 patients) demonstrated targeting precision within a millimeter for all 3 coordinates. There was 1 complication, a bleed in the target with ischemia in the motor thalamus, which led to the introduction of 2 safety measures, that is, the detection of a potential cavitation by a cavitation detector and the maintenance of sonication temperatures below 60°C. Conclusions The authors assert that tcMRgFUS represents a noninvasive, precise, and radiation-free neurosurgical technique for the treatment of neuropathic pain. The procedure avoids mechanical brain tissue shift and eliminates the risk of infection. The possibility of applying sonication thermal spots free from trajectory restrictions should allow one to optimize target coverage. The real-time continuous MR imaging and MR thermometry monitoring of targeting accuracy and thermal effects are major factors in optimizing precision, safety, and efficacy in an outpatient context.

DOI: https://doi.org/10.3171/2011.10.FOCUS11248

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-56006
Published Version

Originally published at:
Jeanmonod, D; Werner, B; Morel, A; Michels, Lars; Zadicario, E; Schiff, G; Martin, E (2012). Transcranial magnetic resonance imaging-guided focused ultrasound: noninvasive central lateral thalamotomy for...
DOI: https://doi.org/10.3171/2011.10.FOCUS11248
Transcranial magnetic resonance imaging–guided focused ultrasound: noninvasive central lateral thalamotomy for chronic neuropathic pain

DANIEL JEANMONOD, M.D.,1,2 BEAT WERNER, M.Sc.,3 ANNE MOREL, Ph.D.,1,4 LARS MICHELS, Ph.D.,1,3 EVAL ZADICARIO, M.Sc.,5 GILAT SCHIFF, B.Sc.,5 AND ERNST MARTIN, M.D.3

1Department of Functional Neurosurgery and 4Center for Clinical Research, University Hospital Zürich; 2Center of Ultrasound Functional Neurosurgery, Solothurn; 3MR-Center, University Children’s Hospital, Zürich, Switzerland; and 5InSightec, Ltd., Tirat Carmel, Israel

Object. Recent technological developments open the field of therapeutic application of focused ultrasound to the brain through the intact cranium. The goal of this study was to apply the new transcranial magnetic resonance imaging–guided focused ultrasound (tcMRgFUS) technology to perform noninvasive central lateral thalamotomies (CLTs) as a treatment for chronic neuropathic pain.

Methods. In 12 patients suffering from chronic therapy-resistant neuropathic pain, tcMRgFUS CLT was proposed. In 11 patients, precisely localized thermal ablations of 3–4 mm in diameter were produced in the posterior part of the central lateral thalamic nucleus at peak temperatures between 51°C and 64°C with the aid of real-time patient monitoring and MR imaging and MR thermometry guidance. The treated neuropathic pain syndromes had peripheral (5 patients) or central (6 patients) origins and covered all body parts (face, arm, leg, trunk, and hemibody).

Results. Patients experienced mean pain relief of 49% at the 3-month follow-up (9 patients) and 57% at the 1-year follow-up (8 patients). Mean improvement according to the visual analog scale amounted to 42% at 3 months and 41% at 1 year. Six patients experienced immediate and persisting somatosensory improvements. Somatosensory and vestibular clinical manifestations were always observed during sonication time because of ultrasound-based neuronal activation and/or initial therapeutic effects. Quantitative electroencephalography (EEG) showed a significant reduction in EEG spectral overactivities. Thermal ablation sites showed sharply delineated ellipsoidal thermal lesions surrounded by short-lived vasogenic edema. Lesion reconstructions (18 lesions in 9 patients) demonstrated targeting precision within a millimeter for all 3 coordinates. There was 1 complication, a bleed in the target with ischemia in the motor thalamus, which led to the introduction of 2 safety measures, that is, the detection of a potential cavitation by a cavitation detector and the maintenance of sonication temperatures below 60°C.

Conclusions. The authors assert that tcMRgFUS represents a noninvasive, precise, and radiation-free neurosurgical technique for the treatment of neuropathic pain. The procedure avoids mechanical brain tissue shift and eliminates the risk of infection. The possibility of applying sonication thermal spots free from trajectory restrictions should allow one to optimize target coverage. The real-time continuous MR imaging and MR thermometry monitoring of targeting accuracy and thermal effects are major factors in optimizing precision, safety, and efficacy in an outpatient context.

(http://thejns.org/doi/abs/10.3171/2011.10.FOCUS11248)

Key Words • central lateral thalamotomy • neuropathic or neurogenic pain • transcranial magnetic resonance imaging–guided focused ultrasound

Considering the inherent risks related to neurosurgical procedures, such as infections and hemorrhages, there is an obvious demand for less invasive alternative procedures. Following extensive preclinical investigations4–8,10,11,13,15,24,25,31,32 a clinically relevant prototype of a tcMRgFUS device for thermal ablation was developed.9,12,14 Because of its noninvasiveness, focused ultrasound technology eliminates the risk of infection, reduces the risk of bleeding, and limits collateral damage to nontargeted tissue. Magnetic resonance imaging allows precise intra-procedural localization of the ablation target, definition and verification of safety margins for the ultrasound treatment, real-time monitoring of thermal ablation dynamics, and intra- and posttreatment assessment of intervention results.2,3,21 The tcMRgFUS technique involves the transformation of sonic into thermal energy and the production of a thermoablation. The possibility of
applying this technique transcranially (that is, without injury to skin and skull) has great potential in the field of neurosurgery.\textsuperscript{16,22}

A recent landmark clinical study\textsuperscript{23} examined the feasibility and initial technical results of tcMRgFUS and showed for the first time in 3 patients that it is possible to focus the ultrasound beam through the intact skull into the brain and to visualize internal heating at the focal point and on the brain surface by using MR imaging temperature mapping. These findings constitute a significant step forward in establishing an entirely noninvasive alternative therapy to surgery for brain disorders.

Based on our long-term clinical experience in functional neurosurgery for neuropathic (or neurogenic) pain with radiofrequency stereotactic interventions in the medial thalamus\textsuperscript{17,19,20} and after preclinical studies with phantoms, biological tissues, and ex vivo human head preparations, we adapted our interventional procedure to perform CLTs in patients suffering from chronic neuropathic pain using the tcMRgFUS technology. The study was approved by the ethics committee of Zurich University and the state of Zurich (Kantonale Ethikkommission des Kantons Zürich). An initial report about the short-term results for 9 patients has already been published.\textsuperscript{26} The present report provides clinical and neurophysiological results over 1 year as well as analyses of the targeting precision and the postoperative MR imaging visualization of the produced thermolesions.

\section*{Methods}

\textbf{Patient Population}

Twelve patients with chronic therapy-resistant neuropathic pain were enrolled for tcMRgFUS CLT and provided their written informed consent. For the sake of safety, a thermal spot of only 42°C was placed in the first patient. This intervention did not result in a thermolesion and this patient was excluded from further analysis. Therapy resistance was established based on the lack of efficacy and/or the side effects of antiepileptic and antidepressant drugs. Patients were 45–75 years old and suffered from facial pain (3 patients), thoracic pain (1 patient), lower-extremity pain (3 patients), upper-extremity pain (4 patients), and hemibody pain (1 patient), of central (6 patients) or peripheral (5 patients) origin (Table 1). The causal lesions at the origin of the different neuropathic pain syndromes were amputation (phantom limb pain, 1 patient), root compression in failed-back surgery syndrome (1 patient), root compression by neurinoma (1 patient), herpes zoster infection (1 patient), nerve trauma (1 patient), spinal cord lesion (2 patients), putaminal lesion (1 patient), brachial plexus avulsion (2 patients), and thalamic infarct (1 patient). The duration of pain before treatment was between 1.5 and 21 years (mean 8.5 years). A pre- and postoperative pain assessment was performed using a detailed questionnaire, including the items of the McGill Pain Questionnaire. The VAS rating of pain intensity was noted for the least and worst pain intensities on a scale between 1 and 100. In addition, patients provided a global percentage value of postoperative pain relief as compared with the preoperative state. In patients with chronic therapy-resistant neuropathic pain, a pain relief scale and VAS value comparisons for pain intensity reduction after treatment are the most adapted and commonly recognized assessment indicators to serve as primary outcome measures for success. Patients were clinically examined as follows: repetitive assessments during the treatment (see below); clinical examination on the evening of the treatment day and 24 and 48 hours afterward; telephone consultation at 1 month after treatment; and full reassessment at 3 months and 1 year after treatment.

Prior to treatment, the patients underwent CT scanning (512 × 512 matrix, 1-mm slice thickness) that covered the entire cranium as well as an MR imaging examination with T1- and T2-weighted images and DT imaging.

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|c|c|c|c|}
\hline
Case No. & Duration of Pain (yrs) & Location of Pain & Cause of Pain & CLT Side & Max Temp at Target (°C) & Sensory Improvements & Activation Effects \\
\hline
1 & 6 & leg & root compression (disc herniation) & lt/rt & 53 & + & paresthesias in leg \\
2 & 8.5 & hemibody & thalamic infarct & lt & 51 & + & vestibular, pain in head \\
3 & 2.5 & face & traumatic trigeminal nerve injury & rt\textsuperscript{†} & 57 & + & vestibular, pain in face \\
4 & 1.5 & face & striatal & rt & 59 & - & vestibular, nausea, paresthesias in face, pain in face \\
5 & 4 & face & postherpetic neuralgia & lt/rt & 55 & + & absent \\
6 & 9 & arm & root compression (neurinoma) & lt/rt\textsuperscript{†} & 58 & + & vestibular, vomiting, pain in head \\
7 & 17 & arm & avulsion of brachial plexus & lt/rt\textsuperscript{†} & 57 & - & vestibular, pain in head, paresthesias in arm \\
8 & 8 & leg & phantom leg pain & rt\textsuperscript{†} & 55 & - & pain in head \\
9 & 16 & arms & paraplegia & lt/rt & 60 & - & vestibular, pain in leg \\
10 & 7 & thorax & syringomyelia & lt/rt & 64 & + & vestibular, pain in head, nausea \\
11 & 21 & arm & avulsion of brachial plexus & lt & 64 & - & vestibular, paresthesias, pain in head \\
\hline
\end{tabular}
\caption{Summary of clinical and treatment data in 11 patients who underwent tcMRgFUS*}
\end{table}

* The mean duration of pain among the patients was 8.5 years. Neurological deficits occurred in only one patient (Case 11): neglect and dysmetria because of bleeding and ischemia. Abbreviation: Temp = temperature; + = improvement; − = no change.

\textsuperscript{†} Complement to radiofrequency CLT.
Focused ultrasound for central lateral thalamotomy

Identiﬁcation. Identical MR imaging series were obtained at 2 days, 3 months, and 1 year postsonication.

Surgical Procedure

The treatment was performed in a 3-T MR imaging system (Signa HDx, GE) using the ExAblate 4000 device (InSightec), which features a 30-cm-diameter hemispherical 1024 element phased-array transducer operating at 650 kHz and held by a mechanical positioner. Magnetic resonance imaging was performed using an 8-channel torso phased-array coil.

The patient’s scalp was fully and closely shaved, and the head was immobilized by fixation in an MR imaging–compatible frame (Radionics; Fig. 1). A circular ﬂexible silicone membrane with a central hole was stretched around the patient’s head and sealed to the outer face of the transducer to contain the degassed and chilled (15°C–20°C) water that was circulated in the area between the head and the transducer. This membrane is tight enough to prevent water leakage without preventing blood circulation to the scalp.

Axial and sagittal T1- and T2-weighted fast spin echo images were obtained and coregistered to the previously acquired MR and CT images and to the current MR imaging/transducer coordinates. These images allowed us to calibrate the system and to produce precise stereotactic planes for target determination. The target area, the CLp, was localized on 3D T1-weighted MR images using the stereotactic multiarchitectonic Morel atlas of the human thalamus and basal ganglia.27 The coordinates of the targets were then entered into the planning software of the tcMRgFUS system.

Several low-power sonications of 10–20 seconds duration were applied to induce peak temperatures of 39°C–42°C, known to be below the ablation threshold. They allowed us to assess the exact position and size of the thermal spot and the overall safety proﬁle of the applied sonication parameters.15 Several high-power sonications were then applied in an iterative process guided by MR imaging and MR thermometry, with stepwise increases in the acoustic power and energy to ﬁnally achieve a peak temperature at the target between 51°C and 64°C (Fig. 2). The ﬁnal peak temperature in each treatment is an outcome of various factors. Thermocoagulation effects on tissue can be produced and visualized from 50°C and up, with a 100% necrosis considered to arise at 55°C–57°C. Optimal coverage of the target and the clinical feedback from patients both play a role in determining the ﬁnal peak temperatures. These factors explain their range between 55°C and 64°C for the 9 patients with complete lesioning (see Clinical Results). Typically, we applied sonications of 10 to 20 seconds in duration with up to a maximum acoustic power of 1200 and 800 W, respectively, corresponding to 12,000 J per sonication. The mean peak focal temperature achieved in the treatments was 53 ± 3.3°C (range 48°C–61°C).

Patients were fully awake and responsive during all stages of the intervention. The only medication administered before the procedure consisted of lorazepam 2.5 mg orally. In 2 patients, a subcutaneous opiate injection was necessary because of back pain due to a motionless supine position on the MR imaging table for an extended period of time. During the entire series of sonications, patients were examined and questioned repeatedly to ensure their neurological integrity and to assess 1) changes in pain qualities, extension, and intensity; 2) potential somatosensory improvements; 3) the appearance of somatosensory, vestibular, and vegetative manifestations experienced during the treatment; and 4) the absence of any motor or somatosensory deﬁcit.

The CLT was performed unilaterally (contralateral to the pain location) in 5 patients and bilaterally in 6 patients. A bilateral CLT is, in general, necessary, and it is as sparing of brain functions as a unilateral one.19 In 4 patients, the tcMRgFUS treatment complemented a previously performed radiofrequency treatment. The CLT was performed unilaterally for the following reasons: complement to radiofrequency treatment (2 patients), appearance of bleeding (1 patient; see Clinical Results), immediate 100% pain relief after treatment of the ﬁrst side (1 patient), and intolerance of a longer intervention time (1 patient).

Target Reconstruction Method

To evaluate the accuracy of tcMRgFUS targeting, the 3D coordinates of the centers of the sonication lesions, outlined on T2-weighted MR images obtained 48 hours after sonication, were measured and compared with presurgical stereotactic coordinates of the ablation targets. The dorsoventral coordinates were determined by the distance from the anterior commissure–posterior commissure plane passing through the center of the anterior and posterior commissures (on sagittal and/or coronal MR imaging); the anteroposterior coordinates, by the distance from the posterior commissure (on axial and sagittal MR imaging); and the mediolateral coordinates, by the distance from the thalamoventricular border (on coronal and axial MR imaging).
Quantitative EEG Procedure

Electroencephalography recording was performed at the time of clinical assessment, before entry into the study. The clinical states of the patients, reassessed at the time of enrollment in the month before treatment, remained unchanged, requiring no repetition of EEG recordings. A 10-minute EEG recording was monitored during alternating eyes-open and eyes-closed states (2 blocks with eyes open and 2 blocks with eyes closed). The EEG activity was recorded from a cap with 60 scalp channels (EasyCap) using a 500-Hz sampling rate, 32-mV input range, and 0.1- to 250-Hz bandpass filters. The impedance was kept below 20 kΩ. Electrodes were mounted according to the 10–20 system plus the following 10–10 system sites: FPz, AFz, FCz, CPz, POz, Oz, Iz, F5/6, FC1/2/3/4/5/6, FT7/8/9/10, C1/2/5/6, CP1/2/3/4/5/6, TP7/8/9/10, P5/6, PO1/2/9/10, O1/2. Both O1/2 and FP1/2 were placed 2 cm laterally from the standard positions for more even coverage. Note that F1 served as the recording reference and F2 was the ground electrode. Two additional electrodes were placed below the outer canthus of each eye to measure for electrooculography.

BrainVision Analyzer software (version 1.05, Brain Products) served for offline processing of the EEG. Subsequently, electrooculography channels were discarded from further analysis. Data were digitally bandpass filtered (0.5–70 Hz, 24 dB/oct, and 50-Hz notch) and downsampled to 250 Hz. An infomax independent component analysis was calculated to remove artifacts related to eye movements, eye blinks, and muscle contractions. Movement-related artifacts, which may not be suitable for independent component analysis correction, were excluded from the unmixing procedure. Components were profiled by their topography, activation time course, and spectrogram. After artifact removal, the components were first back-projected to the EEG and then transformed to the average reference. Segments with remaining artifacts were marked and excluded from successive analysis (mean length of the EEG was about 4 minutes for each resting state condition). Next, the data were parsed into 2-second epochs. Absolute spectral power was estimated for each epoch using fast Fourier transform (Hanning window: 10%, zero-padded, resolution 0.5 Hz). The mean spectral band power was calculated from 1–48 Hz. Spectral bands were defined as follows: delta (2–4 Hz), theta (4–8 Hz), alpha1 (8–13 Hz), and beta (13–30 Hz). (Note that the superior spectral band limit is included only in the next higher band.) The EEG was analyzed in terms of absolute spectral power as well as electrode-wise comparisons to preserve topographic information (topoplots). For each separate condition, spectral power values were averaged across fast Fourier transform epochs and aver-

**Fig. 2.** Screenshot of the ExAblate 4000 display showing a series of proton resonance frequency MR images (obtained every 3.7 seconds, upper) and a series of magnitude images (center). Magnification of a proton resonance frequency picture (lower left) showing in the center a thermal spot centered in the calculated target display (blue rectangle). Display (lower right) showing the applied acoustic energy, sonication duration, acoustic power, target coordinates, thermal scan parameters, and temperature curve.
Focused ultrasound for central lateral thalamotomy

aged within the above frequency bands. Group means were compared using t-statistics (p < 0.05 indicated significance).

Results

Clinical Results

In the first 2 patients of this series, the therapeutic lesions placed in the CLp, as seen 48 hours after treatment on T2-weighted and DT images, were too small to cover it in any sufficient manner. The tcMRgFUS treatment could thus be considered complete in only 9 of the 11 patients. An analysis of global pain relief percentages as reported by the patients and of VAS values was performed for these 9 patients only; results are listed in Table 2. The preoperative mean VAS score was 59.5/100. Significant pain relief (mean group value 55%) was already reported during and at the end of the procedure. More reliable pain relief percentages were collected at 2 days (mean group value 71.1%, 9 patients), 3 months (mean group value 49.4%, 9 patients), and 1 year (mean group value 56.9%, 8 patients) after treatment. The postoperative mean VAS score was 34.3/100 at 3 months and 35.3/100 at 1 year, representing a 42.3% and 40.7% postoperative improvement, respectively.

At the 1-year follow-up, among 8 patients, 5 took no drugs against pain, but 3 maintained a globally unchanged regimen. Drug intake is, for many reasons, not a good marker of the postoperative evolution of patients who have suffered from long-standing, therapy-resistant neuropathic pain. On the one hand, some patients may have stopped their drug intake before the intervention because of insufficient or absent efficacy or because of side effects. On the other hand, some patients have habituated to their drugs for years and are afraid to reduce or stop them, making a consequent and predetermined drug reduction program practically and ethically impossible.

Lesion Coordinate Reconstruction for Assessment of Targeting Precision

The sonication lesions were at best visible 48 hours after the intervention (Fig. 3 upper) and consisted of a mostly hyperintense ellipsoid lesion with a diameter of 3–4 mm and a length of 4–5 mm. It was surrounded by a

<p>| TABLE 2: Summary of postoperative data in 11 patients who underwent tcMRgFUS* |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|</p>
<table>
<thead>
<tr>
<th>Case No.</th>
<th>Acute Relief (%)</th>
<th>2 Days Relief (%)</th>
<th>3 Mos Relief (%)</th>
<th>1 Yr Relief (%)</th>
<th>Before Sonication VAS Score</th>
<th>3 Mos After Sonication VAS Score</th>
<th>1 Yr After Sonication VAS Score</th>
<th>1 Yr Postop Drug Intake</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>100</td>
<td>70</td>
<td>0</td>
<td>lost to FU</td>
<td>70–80</td>
<td>16–79</td>
<td>UN</td>
<td>reduced†</td>
</tr>
<tr>
<td>2</td>
<td>30</td>
<td>30</td>
<td>0–30</td>
<td>lost to FU</td>
<td>72–100</td>
<td>40–70</td>
<td>UN</td>
<td>unchanged</td>
</tr>
<tr>
<td>3</td>
<td>10</td>
<td>100</td>
<td>80</td>
<td>80</td>
<td>52–73, 62.5</td>
<td>5–20, 12.5</td>
<td>9–16, 12.5</td>
<td>stopped</td>
</tr>
<tr>
<td>4</td>
<td>70</td>
<td>50</td>
<td>50</td>
<td>95</td>
<td>40–80, 60</td>
<td>0–72, 36</td>
<td>9–36, 22.5</td>
<td>stopped</td>
</tr>
<tr>
<td>5</td>
<td>100</td>
<td>80</td>
<td>0</td>
<td>deceased‡</td>
<td>12–78, 45</td>
<td>0–50, 25</td>
<td>UN</td>
<td>UN</td>
</tr>
<tr>
<td>6</td>
<td>30</td>
<td>100</td>
<td>90</td>
<td>100</td>
<td>39–62, 50.5</td>
<td>0–11, 5.5</td>
<td>0</td>
<td>stopped</td>
</tr>
<tr>
<td>7</td>
<td>30</td>
<td>50</td>
<td>50</td>
<td>40</td>
<td>22–85, 53.5</td>
<td>15–84, 49.5</td>
<td>21–86, 53.5</td>
<td>unchanged</td>
</tr>
<tr>
<td>8</td>
<td>100</td>
<td>100</td>
<td>70</td>
<td>50</td>
<td>56–85, 70.5</td>
<td>13–80, 46.5</td>
<td>77</td>
<td>unchanged</td>
</tr>
<tr>
<td>9</td>
<td>0</td>
<td>10</td>
<td>0</td>
<td>0</td>
<td>67–90, 78.5</td>
<td>54–89, 71.5</td>
<td>11–84, 47.5</td>
<td>unchanged</td>
</tr>
<tr>
<td>10</td>
<td>100</td>
<td>75</td>
<td>90</td>
<td>80</td>
<td>44–91, 67.5</td>
<td>0–14, 7</td>
<td>0–28, 14</td>
<td>stopped</td>
</tr>
<tr>
<td>11</td>
<td>75</td>
<td>15</td>
<td>10</td>
<td>0</td>
<td>25–70, 47.5</td>
<td>30–80, 55</td>
<td>30–80, 55</td>
<td>stopped</td>
</tr>
<tr>
<td>overall mean§</td>
<td>55</td>
<td>71.1</td>
<td>49.4</td>
<td>56.9</td>
<td>59.5</td>
<td>34.3</td>
<td>35.3</td>
<td>UN</td>
</tr>
</tbody>
</table>

* FU = follow-up; UN = unavailable.
† Includes opiates.
‡ Unrelated medical cause.
§ The mean values for global pain relief and VAS were calculated for Cases 3–11 only.
fuzzy and irregularly shaped area of perifocal vasogenic edema, which completely receded over a month. Lesions were significantly smaller at 3 and 12 months after treatment (Fig. 3 center and lower). A detailed neuroradiological description of the sonication lesions was previously published.26

The median and mean (± standard deviation) of the targeting accuracy are given in millimeters in Table 3 for the patients in Cases 1–9 and separately for the first and second groups treated sequentially. The deviations for the first group (5 patients, 9 lesions) are larger in all axes than for the second group (4 patients, 9 lesions) treated after the implementation of procedural improvements, that is, better accuracy in the thermal spot realignment during the verification phase at low temperatures, and an optimization of the determination of the center frequency of the MR acquisition for proper thermal imaging projection. The increased accuracy between the 2 subgroups was most marked in the anteroposterior direction (from 1.17 ± 0.58 to 0.39 ± 0.46 mm). The mean values for the whole group are < 1 mm in all axes, but larger in the mediolateral axis than in the other axes.

Localization of the tcMRgFUS lesions in the thalamus is illustrated in Fig. 4. Projections of the lesions onto horizontal sections of the Morel atlas27 showed the following: of 18 lesions, 7 enclosed most, if not the whole, anteroposterior extent of the CLp (targeted in CLT); 5 enclosed half of it; and 6 enclosed up to one-third. Most partial CLT lesions encroached onto the pulvinar, and only 2 encroached on the posteriormost part of the mediodorsal nucleus. The first series of lesions (Cases 1–5, Subgroup 1) tended to be more posterior and overlapped less with the CLp than the rest of the lesions (Cases 6–9, Subgroup 2). This result corresponds to the measurements shown in Table 3. Note that in the patients in Cases 3, 6, and 7, a part of the excentering of the focused ultrasound lesions...
Focused ultrasound for central lateral thalamotomy

**TABLE 3: Precision of tcMRgFUS targeting**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Total Patients Mean ± SD</th>
<th>Median</th>
<th>Subgroup 1 Mean ± SD</th>
<th>Median</th>
<th>Subgroup 2 Mean ± SD</th>
<th>Median</th>
</tr>
</thead>
<tbody>
<tr>
<td>dorsoventral</td>
<td>0.58 ± 0.63</td>
<td>0.5</td>
<td>0.61 ± 0.57</td>
<td>0.5</td>
<td>0.56 ± 0.68</td>
<td>0</td>
</tr>
<tr>
<td>anteroposterior</td>
<td>0.78 ± 0.65</td>
<td>1.0</td>
<td>1.17 ± 0.58</td>
<td>1.5</td>
<td>0.39 ± 0.46</td>
<td>0</td>
</tr>
<tr>
<td>mediolateral</td>
<td>0.83 ± 0.78</td>
<td>0.5</td>
<td>1.01 ± 0.85</td>
<td>0.7</td>
<td>0.82 ± 0.79</td>
<td>0.5</td>
</tr>
</tbody>
</table>

* Values of dorsoventral, anteroposterior, and mediolateral differences between centers of the sonication lesions and presurgical target coordinates are expressed in mm.

is related to target adaptations due to previously made radiofrequency CLT lesions and not only to suboptimal procedural factors.

**Quantitative EEG Assessment**

The spectral comparison of the 8 patients who underwent a 3- and 12-month follow-up EEG recording revealed 2 major findings. First, spectral power was elevated in all frequency bands (delta–beta) before the sonication (Fig. 5 upper). Second, frequency band–specific spectral power amplitudes were reduced 3 and 12 months after the sonication, and thus were approaching the spectral curve of healthy volunteers. An electrode-wise comparison of frequency band–specific spectral power showed that several scalp locations displayed significantly elevated power before as compared with 12 months after sonication (Fig. 5 lower). On the topoplots featured in Fig. 5, black dots indicate the electrodes, which show significantly (p < 0.05, t > 2) higher spectral power before as compared with 12 months after sonication, in delta (2–4 Hz) and theta (4–8 Hz) bands at frontal, centrotemporal, and parietal electrodes; and in alpha (8–13 Hz) and beta (13–30 Hz) bands at centroparietal electrodes.

**Discussion**

This report on the clinical, neurophysiological, and neuroanatomical results of tcMRgFUS CLT for neuropathic pain demonstrates the precision and efficacy of this surgical approach and confirms the short-term results reported previously. The clinical results presented here support our long experience with radiofrequency CLT treatment for chronic therapy-resistant neuropathic pain. The patients in this series showed a typical mean group pain relief profile across time, from 71% at 2 days after treatment to 49% at 3 months and 57% at 1 year after treatment. The VAS improvement was similar at 3 months (42%) and at 1 year (41%). This profile can be explained as follows: the immediate reduction of low-frequency overactivity using CLT provides the patient with acute relief. However, complex nonlinear systems, like the thalamocortical system, display typically protracted dynamics when they change from one activity level to another and search for a new resting state. This explains why the EEG spectral improvements, in parallel with clinical relief, develop over at least 1 year. After the initial pain relief and as the thalamocortical network just begins its retuning (reorganization) toward normal activity, emotional, cognitive, and social factors intervene and influence the patient’s evolution as he or she revisits specific personal goals put aside because of chronic pain and progressively adapts to new individual goals and concepts. This endeavor becomes less and less demanding as time goes by and the thalamocortical network comes closer to normality.

Previous studies have related the clinical phenomenon of chronic neuropathic pain to an increase in low- and high-frequency spectral EEG and magnetoencephalography activities. This correlation is further supported by the evidence of reduced theta overactivity in the EEG recordings of patients treated with CLT. Electroencephalography spectral analysis can thus be used as an additional tool to diagnose chronic neuropathic pain states and monitor their postoperative evolution. The EEG spectral data presented here are fully compatible with these studies and demonstrate 1) EEG overactivities in all frequency domains and 2) their reduction, particularly strong in the beta range, after the tcMRgFUS treatment. They serve as additional evidence in favor of thalamocortical mechanisms being at the source of neuropathic pain.

The absence of postoperative clinical deficits, known for years about medial thalamotomies, has been confirmed for CLT, a medial thalamotomy centered on the CLp where an abnormal low-threshold calcium spike burst activity was recorded. Results in the present study confirm the sparing mode of action of CLT, which selectively targets dysfunctional thalamocortical regulators, initiating a resumption of normal thalamocortical dynamics while sparing all functions supported by unaffected thalamocortical regulators and executors. The absence of postoperative kindling of new neuropathic pain mechanisms has been shown years after CLT and can be related to the selective reduction of the thalamocortical pathophysiology at the source of neuropathic pain phenomena. Six patients experienced immediate and significant somatosensory improvements, which persisted at the 3-month and 1-year follow-ups. This result corresponds with observations after radiofrequency lesions and can also be related to the reduction of thalamocortical overactivity by CLT.

Effects during sonication, whether somatosensory, vestibular, or vegetative, were observed in all patients. They may have 2 origins: 1) an activation of neurons during the few seconds before the thermal ablation effect and 2) initial manifestations of the resumption of a more normal thalamocortical dynamics, as is routinely seen in our experience with radiofrequency CLT, thereby indicat-
ing appropriate target placement. To monitor safety and acquire real-time feedback and information, the presence of a clinician by the patient's side throughout the treatment phase is required. This practice ensures that the sonication effects, including changes in neurological parameters, as well as patient safety and comfort during the extended period of time in the MR imaging unit are closely monitored.

The tcMRgFUS CLT thermoablations as seen on MR imaging 2 days after sonication were surrounded by a vasogenic edema, which was no longer visible after 1 month. Visualization of the thermoablation itself receded between 1 and 3 months. These observations are indicative of a selective neuronal coagulation with few hemorrhagic components, which are often seen with radiofrequency thermoablations and correlate with a much longer 

Fig. 4. Localization of tcMRgFUS lesions in the medial thalamus for 9 patients treated for neurogenic pain. The size of the lesions (4-mm diameter) corresponds closely with the extent of Zone II seen in the 2-days postoperative axial T2-weighted MR image (lower left). The location of the lesion in relation to the CLp is determined by projection of the corresponding atlas maps (6.3 [upper] and 8.1 [lower right] mm dorsal to the intercommissural plane) onto the MR image by using the position of the posterior commissure (pc, dotted line) for alignment. The 2 lesions projected on the MR image are the 2 anteriormost lesions in the patient in Case 9 (lower right). CL = central lateral; LP = lateral posterior; MDmc = mediodorsal magnocellular division; MDpc = mediodorsal parvocellular division; MDpl = mediodorsal paralamellar division; PuM = medial pulvinar; Pv = paraventricular; R = reticular thalamic nucleus; sm = stria medullaris; VLPd = ventral lateral posterior, dorsal division; VLPp = ventral lateral posterior, posterior part.
Focused ultrasound for central lateral thalamotomy

maintenance of edema. With tcMRgFUS, there is no mechanical trauma of the target tissue, and the temperature at the center of the hotspot is not as high as with radiofrequency ablation. With radiofrequency ablation, the temperature, depending on the electrode geometry, must be much higher than 60°C at the electrode tip to achieve the necessary heating over the desired target volume. At 48 hours postsonication, the blood-brain barrier was seen to be closed.26 All of these observations are compatible with a clean thermolesion displaying a fast healing process and speak against the possibility of unexpected deleterious long-term tissue phenomena. In this context, the bleeding that occurred in our last patient demands an explanation, particularly since he presented no increased risk factors (he had normal blood pressure and coagulation). A detailed case study was performed to analyze the factors that might have facilitated this event. Two factors were considered: first, the possibility of the development of a cavitation effect, although a detailed analysis provided no direct evidence in its favor. Nevertheless, this possibility requires the installation of a cavitation detector to detect and stop this phenomenon as soon as it appears. Second, a temperature-related factor must be considered, supported by published evidence32 and confirmed by recent experimental data collected in the context of this case study. Accordingly, we recommend maintaining the sonication

![Graph showing power spectral curves of the patients before and after surgery with standard deviations of the means (vertical bars). Black curve is for controls. Frequency bands are shown in yellow at the bottom of the graph.](image)

**Fig. 5.** Upper: Graph showing power spectral curves of the patients before and after surgery with standard deviations of the means (vertical bars). Black curve is for controls. Frequency bands are shown in yellow at the bottom of the graph. Lower: Topoplots showing electrode-wise comparisons. Black dots indicate the electrodes, which showed significantly higher spectral power before surgery as compared with 12 months after surgery.
temperatures below 60°C. Note that the bleeding itself, centered in the adequately targeted CLp, did not produce deficits. It is the ischemia, extending anteriorly and laterally into the VLp, that caused the typical motor symptomatology. We hypothesize a blood-induced vasospasm in the VLp as a causal link between the 2 events.

Our target reconstructions demonstrate precision within a millimeter for all 3 target coordinates. The classic stereotactic techniques involving penetration of an electrode into the brain cannot, despite adequate technological accuracy, reach such final precision because of the unforeseeable mechanical shift of brain tissue by the electrode. In addition, the tcMRgFUS CLT should allow for optimal target volume coverage thanks to the absence of electrode trajectory restrictions. Such optimization should develop with increased procedural experience and further technological developments, both decreasing the time devoted to optimal target coverage during treatment. This should correlate with higher long-term pain relief scores as compared with our previous results with CLT. The patient group in the present study is too small to be conclusive on this question, and further long-term studies on larger patient groups will have to verify whether this is indeed the case. Sonication also proved to be particularly helpful for 4 patients who had previously been treated with radiofrequency CLT, facilitating the complementary treatment by avoiding potential shifts of penetrations through gliotic tissue.

Conclusions

Results of the current study highlight the precision and efficiency of tcMRgFUS for treating chronic neuropathic pain. The noninvasiveness of the procedure and specifically the continuous MR imaging and MR thermometry monitoring of the intervention represent major factors toward an optimization of safety conditions. This radiation-free technology can be applied to other functional brain disorders as well as to numerous other neurosurgical indications and is an important option because of the elimination of brain tissue shift or trauma during therapy. Besides, tcMRgFUS has a probably reduced bleeding risk, no risk of intracranial infection, and is not limited in target coverage by trajectory constraints.

Disclosure

This work was supported by the University of Zürich, the Swiss Federal Institute of Technology Zürich, the University Children’s Hospital Zürich, the Swiss National Center of Competence in Research (NCCR) “Computer Aided and Image Guided Medical Interventions”, the Focused Ultrasound Surgery Foundation (Charlottesville, VA), and the Sanitas Hospital in Kirchberg. Mr. Zadicario is an employee of InSightec, Ltd.

Author contributions to the study and manuscript preparation include the following. Conception and design: Jeanmonod, Werner, Morel, Michels, Zadicario, Martin. Acquisition of data: Jeanmonod, Werner, Morel, Michels, Schiff, Martin. Analysis and interpretation of data: Jeanmonod, Morel, Michels, Schiff, Martin. Drafting the article: Jeanmonod, Morel, Michels, Schiff, Martin. Critical revising the article: all authors. Reviewed submitted version of manuscript: Jeanmonod, Werner, Morel, Zadicario, Schiff, Martin. Approved the final version of the manuscript on behalf of all authors: Jeanmonod. Statistical analysis: Morel, Michels.

Acknowledgments

The authors are most grateful for the technical support of InSightec, Ltd. They thank M. Gallay and A. Poveda-Ramos for intraoperative patient monitoring and support.

References

17. Jeanmonod D, Magnin M, Morel A: Low-threshold calcium
Focused ultrasound for central lateral thalamotomy


Manuscript submitted September 15, 2011.

Accepted October 27, 2011.

Please include this information when citing this paper: DOI: 10.3171/2011.10.FOCUS11248.

Address correspondence to: Daniel Jeanmonod, M.D., Center of Ultrasound Functional Neurosurgery, Leopoldstrasse 1, 4500 Solothurn, Switzerland. email: daniel.jeanmonod@gmail.com.